Serina Therapeutics Inc Cash Flow Conversion Efficiency
Serina Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Serina Therapeutics Inc (SER) has a cash flow conversion efficiency ratio of -2.415x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.85 Million) by net assets ($1.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Serina Therapeutics Inc (2016–2024)
Cash flow conversion efficiency of Serina Therapeutics Inc from 2016 to 2024. This chart illustrates how Serina Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View SER stock price for real-time trading data and today's change.
Serina Therapeutics Inc Cash Flow Conversion Ratio Explained
Serina Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Serina Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Serina Therapeutics Inc ranked by their cash flow conversion efficiency. Also see SER company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CHARWOOD ENERGY EO -01
F:L5Q
|
N/A |
|
Aqua Corporation Public Company Limited
BK:AQUA
|
0.005x |
|
BMS Celik Hasir Sanayi ve Ticaret AS
IS:BMSCH
|
-0.070x |
|
Leeuwin Metals Ltd
AU:LM1
|
-0.042x |
|
Infoline Tec Holdings Bhd
KLSE:0253
|
-0.190x |
|
Beamr Imaging Ltd. Ordinary Share
NASDAQ:BMR
|
-0.320x |
|
Seres Therapeutics Inc
NASDAQ:MCRB
|
-0.648x |
|
Theta Edge Bhd
KLSE:9075
|
0.228x |
Annual Cash Flow Conversion Efficiency for Serina Therapeutics Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Serina Therapeutics Inc from 2016 to 2024. Review SER FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $508.00K | $-17.14 Million | -33.734x | -44098.95% |
| 2023-12-31 | $-32.29 Million | $-2.48 Million | 0.077x | -36.04% |
| 2022-12-31 | $-17.32 Million | $-2.08 Million | 0.120x | -36.75% |
| 2021-12-31 | $-11.88 Million | $-2.25 Million | 0.190x | -86.92% |
| 2020-12-31 | $-5.40 Million | $-7.82 Million | 1.449x | +137.31% |
| 2019-12-31 | $2.62 Million | $-10.16 Million | -3.882x | -299.69% |
| 2018-12-31 | $8.23 Million | $-8.00 Million | -0.971x | -28.57% |
| 2017-12-31 | $8.32 Million | $-6.29 Million | -0.755x | -300.60% |
| 2016-12-31 | $-22.38 Million | $-8.43 Million | 0.377x | -- |
About Serina Therapeutics Inc
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 … Read more